19:26 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Medix planning Mexican NDA for obesity candidate

Saniona AB (SSE:SANION) said partner Medix Products S.A. de C.V. (Mexico City, Mexico) plans to submit an NDA next half in Mexico for obesity candidate tesofensine (NS2330) after two doses of the compound met the...
00:34 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

Medix Products begins Phase III of obesity candidate

Medix Products S.A. de C.V. (Mexico City, Mexico) began a Phase III trial of tesofensine (NS2330) to treat obesity. The double-blind, placebo-controlled, Mexican trial will evaluate once-daily 0.25 and 0.5 mg doses of tesofensine for...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

Amitifadine: Phase IIb/IIIa data

Top-line data from the double-blind, U.S. Phase IIb/IIIa TRIADE trial in 342 patients with MDD showed that once-daily 50 and 100 mg doses of amitifadine each missed the primary endpoint of improving MADRS score from...
07:00 , May 30, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Approach

This week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Small molecule fruit fly screening platform for regulators of sleep A small molecule fruit fly screening platform could be useful...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

Amitifadine: Completed Phase IIb/IIIa enrollment

Euthymics completed enrollment of 342 patients in the placebo-controlled, double-blind, U.S. Phase IIb/IIIa TRIADE trial comparing 50 and 100 mg amitifadine vs. Paxil paroxetine for 12 weeks in patients with an inadequate response to a...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

EB-1010: Phase IIb/IIIa started

Euthymics began the placebo-controlled, double-blind, U.S. Phase IIb/IIIa TRIADE trial to compare 50 and 100 mg EB-1010 vs. Paxil paroxetine for 12 weeks in about 300 patients. Euthymics gained the compound through its reverse-merger with...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

EB-1010: Phase II data

Data from the modified intent-to-treat (mITT) population (n=56) of a double-blind, U.S. and European Phase II trial showed that EB-1010 met the primary endpoint of significantly improving MADRS total score at week 6 vs. placebo...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Clinical News

Meridia sibutramine: Phase III data

The double-blind, U.S. Phase III SCOUT trial in 10,744 overweight or obese patients >=55 years old with pre-existing cardiovascular disease and/or Type II diabetes showed that Meridia led to a significantly higher rate of primary...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

Tesofensine: Phase III delayed

NeuroSearch said it will not proceed with planned Phase III trials of tesofensine to treat obesity after the trials' proposed active comparator, sibutramine, was pulled from the market in Europe due to cardiovascular safety concerns....
07:00 , Jul 6, 2009 |  BC Week In Review  |  Clinical News

Lu AA24530: Phase II data

H. Lundbeck said top-line results from a double-blind Phase II trial in 652 patients showed 5, 10 and 20 mg Lu AA24530 met the primary endpoint of a significant improvement in MADRS scores after 6...